Сравнение
Liraglutide vs. Survodutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
204656-20-2
2179963-22-7
Молекулярная масса
3751 g/mol
4727 g/mol
Период полувыведения
13 h
168 h
Последовательность
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteМеханизм действия
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
5
4
из них на людях
4
4
Зафиксированные эффекты
3
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Liraglutide and Survodutide?
- Liraglutide is classified as "Метаболизм", while Survodutide is classified as "Метаболизм". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Liraglutide or Survodutide?
- The highest available evidence level is "РКИ на людях" for Liraglutide and "РКИ на людях" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Liraglutide and Survodutide in Germany and the United States?
- Германия: Liraglutide — Рецептурный, Survodutide — Не одобрено. США: Liraglutide — Рецептурный, Survodutide — Не одобрено. These are factual summaries with source and review date on the individual pages.